Company Profiles

driven by the PitchBook Platform

ACS Biomarker

ACS Biomarker
2007 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series A LATEST DEAL TYPE
3 INVESTORS
Description

Operator of a biomedical company focusing on the discovery, validation and commercialization of miRNAs biomarkers for cardiovascular disease. The company conducts miRNA and protein-based biomarker research for the diagnosis, prognosis, and management of cardiac diseases.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Primary Office
Meibergdreef 5
1105 AZ Amsterdam
Netherlands

+31 (0)20 697 1087
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ACS Biomarker’s full profile, request a free trial.

ACS Biomarker Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 20-May-2011 Completed Startup
To view this company’s complete deal history including valuation and funding request access »

ACS Biomarker Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AMC Ventures Holding Venture Capital Minority 000 0000 000000 0
Life Sciences Fund Amsterdam Venture Capital Minority 000 0000 000000 0
Limburg Ventures Venture Capital Minority 000 0000 000000 0

You’re viewing 3 of 3 investors.

ACS Biomarker Executive Team (5)

Name Title Board
Seat
Contact
Info
Marlon Dijkshoorn Chief Financial Officer
Tilman Hackeng Ph.D Chief Technology Officer & Co-Founder
Yigal Pinto Ph.D Chief Scientific Officer & Co-Founder
Mat Daemen Co-Founder
Heico Breek MD Chief Executive Officer

You’re viewing 5 of 5 executives.

ACS Biomarker Board Members (3)

Name Representing Role Since Contact
Info
Harm de Vries Life Sciences Fund Amsterdam Board Member 000 0000
Marcel Kannekens Self Supervisory Board Member 000 0000
Marcel Kloosterman Ph.D Limburg Ventures Board Member 000 0000

You’re viewing 3 of 3 board members.